Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebicotuzumab combined with a PD-1 inhibitor for recurrent nasopharyngeal carcinoma
ChiCTR2600133348Phase 2Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Aug 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebicotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Objective response rate and 1-year and 2-year progression-free survival rates. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
vebicotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600133348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133348.